Schizophrenia. Schizophrenia
Conditions
Interventions
Intervention 1: intervention group: patients will receive a daily 500 mg dose of Curcumin for 8 weeks, in addition to the second-generation antipsychotic medication they were previously taking. This d
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients diagnosed with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders 5(DSM-5) criteria. Consent of the patient’s legal guardian. Calgary Depression Scale for Schizophrenia (CDSS) score less than or equal 18. A positive subscale score is greater than 7 and less than or equal to 28. A negative symptom is greater than or equal to 24 and the presence of at least 2 of the 3 core symptoms (affective flattening, passive/apathetic social withdrawal, and lack of spontaneity and flow of conversation).
Exclusion criteria
Exclusion criteria: Current use of typical antipsychotic medications, antidepressants, Sodium Valproate, and Lithium. Current presence of comorbid psychiatric disorders, including schizoaffective or other psychotic disorders, mood disorders, anxiety disorders (such as panic disorder or obsessive-compulsive disorder), Post-Traumatic Stress Disorder (PTSD), or eating disorders. Current or past (within the last 6 months) diagnosis of severe personality disorders that would compromise the participant's ability to comply with study requirements. Acute substance, drug, or alcohol dependence or abuse currently or within the last 12 months, excluding nicotine. Known hypersensitivity to curcumin or any of the placebo components. Prior use of Curcumin (to be determined by medication history). Current diagnosis of a depressive episode in Schizophrenia based on a high score on the Calgary Depression Scale. Receiving Electroconvulsive Therapy (ECT) during the current hospitalization. Having a serious underlying medical or physical condition or illnesses that may affect the assessment (e.g., severe hearing or vision impairments). Serious suicide attempt currently or in recent history Current or prior use of Clozapine. Pregnancy or breastfeeding. Intellectual disability or other cognitive impairments. Presence of neurological disorders, including dementia, delirium, head trauma, seizure disorder (excluding febrile seizures), or obstructive sleep apnea. Positive Hepatitis B Virus (HBV) antigen. Positive Hepatitis C Virus (HCV) antibody. Positive Human Immunodeficiency Virus (HIV) antibody. Elevated serum transaminases upper limit of normal. Current use of medications that interact with Curcumin, including cinnamon compounds, Triazolam, Carbamazepine, and similar drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive symptoms. Timepoint: Baseline (before intervention) and 2, 4, 6, and 8 weeks after Curcumin initiation. Method of measurement: Scale for Assessment of Positive Symptoms .;Negative symptoms. Timepoint: Baseline (before intervention) and 2, 4, 6, and 8 weeks after Curcumin initiation. Method of measurement: Scale for Assessment of Negative Symptoms. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNeda Sadrizadeh Irani
Ahvaz University of Medical Sciences
Outcome results
None listed